Credit: EASL via Linkedin
June 7, 2024 11:21 AM EDT
R&D

Ali­gos, Ar­bu­tus and oth­ers tout ear­ly he­pati­tis ef­fi­ca­cy da­ta at #EASL24

Katherine Lewin

News Reporter

Max Bayer

Pharma Reporter

At this year’s EASL In­ter­na­tion­al Liv­er Con­gress, Vir took cen­ter stage Wednes­day to re­port ear­ly Phase 2 da­ta for its he­pati­tis D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

Rovi teas­es ac­qui­si­tion of­fers for its CD­MO unit po­ten­tial­ly worth €2B to €3B

A service from the Financial Times